It's Wednesday, finally. DECN was given ample opportunity

New Post Public Reply Private Reply Replies (3) Message Board
AlwaysSum1ElsesFault
848
It's Wednesday, finally. DECN was given ample opportunity to be specific and transparent about the state and accuracy of the test, any to my surprise, they mostly were. Here's a handy scorecard to use to see what goalposts keep getting moved and where all the holes that need to be filled are:

Everyone get nice & familiar with:
http://www.pharmatechsolutions.co/assets/inse...ro!_PP.pdf

Timing matters here. Let's see:

Quote:

First: "ready in the summer of 2020"
But then: "Our plan is designed to bring at least 100,000 of our kits to market in the USA and Canada, and another 100,000 in Europe, during the month of May 2020."
Next: " late summer of 2020"
Now: "September 2020"


Watch that space.

Quote:

As this Coronavirus spread, and with time on their hands during the lock down, we asked The Bio several
days after
their mid-February 2020 lock down
, to look into whether some of our diabetic detection and management
technologies could be put to use to develop a coronavirus test.


March 16:
https://www.accesswire.com/580769/DECN-Update...d-to-480mm

Quote:

We are awaiting release of blood samples from previously infected people in Daegu, Korea, so that we can complete testing and make a final report to the U.S. FDA so that we may secure our Emergency Waiver. In the meantime, all other requests made by the FDA will be met this week and next.


The test is not complete. Additionally, "all other requests" should have been met by now?

Finally, on the 18th, according to DECN, H5N1 was "validated", "most recently the methodologically similar corona virus" is a sentence fragment and doesn't mean anything.

Quote:

GenViro!™ has been validated at the company's R&D center in Daegu, Korea for the H5N1 virus and most recently the methodologically similar corona virus.


So where are the results?

Quote:

A significant change to this policy is that once validation testing for a product has been completed, the test can be distributed to customers, entities and users, with certain labeling and a summary of test results provided on the company website (and/or the package).


Who has The Link for the summary of test results? It's not proprietary or sensitive information... it's going to be on the website and in every box.


Quote:

Keith Berman, CEO of DECN commented, "We have the technology perfected which will take months off of the development schedule. Our impedance powered diagnostic will be field tested at ground-zero in Daegu, Korea, where 700+ people have already been overcome by Coronavirus (COVID19) and where all of the clinical studies for our "Gen" products were tested. Our timing here is spot-on."


Except it isn't. The FDA has approved half a dozen rapid tests just in the past few days, with scores more on the horizon. DECN hasn't even registered for the race yet.

What DECN has is "specs," "guidelines," "methods," "proposals"... watch all the Weasel Words down below..

Quote:

The specifications guidelines set down by Mr. Berman, for creating this Covid-19 testing device and its
important chemistry, were that the test must be measured on the company’s existing Precise or Avantage glucometers,
because they were completed products, having been tested to great length, and now to be adapted for detection of
Covid-19 instead of whole blood glucose
. [what happened to H5N1??] In addition, the resulting chemistry would necessarily run using a patients
(small sample of) whole blood taken from a finger prick, and later defined as 1-2 microliters (a small drop on a finger
tip), and perform the test and provide a result in one minute or less (later redefined as 15 seconds or less), with at least
a 95% accuracy. Mr. Berman believed this device was capable of 97-98% accuracy.


"our screening method should allow for 80% of the suspected carriers of Coronavirus to exit the quarantine systems"

The design above is in many regards similar to the direct antibody antigen approaches favored by some of
the competitive companies in the Covid-19 testing field. But the major difference (magic) is that the approach used
by the company in its GenViro! product allows for swift (15 seconds or less) results using a minimum of blood from
a finger prick. As of this writing, work has commenced on the product specification above with components such as
the platinum electrodes, platinum carbon paste, industrial films (several types) to make the biosensor, and perhaps a
new impedance chip for the meter.


The most immediate request made to the FDA will be for Pre-UEA, the new accepted standard for emergency diagnostic products


I have no idea WTH a Pre-UEA is. Here is the Pre-EUA description:
https://www.fda.gov/emergency-preparedness-an...ostics-fda

Anyone can file a Pre-EUA. You can file a pre-EUA. I can file a pre-EUA. The only thing that matters, is the FDA **GRANTING** an EUA.

Quote:

Our biggest challenge will be meeting the expected crushing demand. For that we prepared, and are interviewing most likely partners currently."

We will discuss partnering potential in a coming release.


Nothing.



Now here's the real kicker... and I know it will come as a shock to many, but both tests require antibodies. Nobody here understands this. And glaringly absent from all of DECN's discussion of these tests is how they plan to get them. This isn't simply chemistry, it's biology as well, and it's way outside of DECN's league. We have not heard "we have a working test for Covid19 and here is a summary of the results" because without those components, they don't have a test. They've given themselves 8 weeks to pull a Hail Mary, but even that is probably too short of a runway. In the meantime:

Abbott - 5 min test, making 50,000 a day:
https://www.forbes.com/sites/brucejapsen/2020...83f8106086


Bodysphere - 2 min test (this is what it looks like when you have a real, functional test):
Quote:

The Los Angeles-based company’s two-minute testing kit uses antibodies in blood to test for current or past infection with a 91% clinical specificity rate and a 99% clinical sensitivity rate, according to a news release. The test delivers results on-site in as fast as two minutes.

Bodysphere said it has contracted cargo planes to deliver the product to the front lines and touted its capability of having millions of test kits reach those front lines within weeks.


https://www.reuters.com/article/us-health-cor...SKBN21I1T7

Qiagen 1 hour, but holy s***, the kitchen sink:

Quote:

The panel can detect and differentiate SARS-CoV-2 and 20 other viral and bacterial pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients, and will become the first "syndromic" testing product to be deployed in the US.

Specifically, the QIAstat-Dx panel is intended for the detection and differentiation of nucleic acid from SARS-CoV-2 as well as adenovirus; four other coronavirus types; human metapneumovirus A+B; influenzas A, A H1, A H3, A H1N1/pdm09, and B types; parainfluenza viruses 1-4; rhinovirus/enterovirus, respiratory syncytial virus A+B, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.... and a partriiiiiiidge in a peeeeaaaarrrrr.... treeeeeeeeeeeeee


https://www.genomeweb.com/pcr/qiagen-receives...oS0KepKiUk

Good lord. That's what a Winner looks like, ladies and gentlemen.

Oh, and not greenlighted YET, but going to kick a** when it does...

Mologic - ***$1*** "pregnancy test (no meter)" style, 10 minute test!:

Quote:

Once ready, the device will allow users to test for exposure to the virus at home, in the community, or in the clinic, providing a result within 10 minutes, without the need for special training, electricity or a laboratory. The company is working in close partnership with the Institut Pasteur de Dakar to validate the COVID-19 test and manufacture at diaTROPiX, a new facility in Senegal. This will be the first time that a diagnostic kit created in the UK will be jointly manufactured in Africa, ensuring tests are available in settings with limited access to laboratory facilities.

Mologic has taken the decision to sell the diagnostic test at cost to low-income settings to ensure affected countries have access to the kits during the global emergency. This will allow high-quality diagnostics to be produced in low-income settings with the aim of ensuring that the test is available to all.



So let's see those results, DECN. Post 'em up on the website, like the FDA requires you to. Somebody won't be getting their EUA until they do!

Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Seatrium, Karpowership Wrap Landmark FSRU Partnership

Updated Category News Views 5

A Milestone in Global Energy Infrastructure Out of Admiralty Yard in Singapore comes a transformation saga that’s begging for attention. Seatrium Limited and Karpowership have pulled off something spectacular with their seventh and final Floating Storage and Regasification Unit (FSRU), LNGT Türkiye. It's not just another vessel hitting the waters—it's the bookend on...

Continue Reading
CATL Opens Europe's Largest Battery Service Hub

Updated Category News Views 5

A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...

Continue Reading
Alex Jones Returns to Austin: New Studio, New Plans

Updated Category News Views 7

Back in the Saddle: Austin's Controversy Stirs Again It looks like we're seeing a new chapter in a saga that just refuses to end. Alex Jones, the infamous firebrand who's plastered conspiracy theories across the airwaves for two decades, is returning to ground zero in Austin—the old InfoWars studio. After wading through bankruptcy muck and courtroom clashes, Jones is...

Continue Reading
Miguel Pantoja: Wiring a Second Chance Beyond Bars

Updated Category News Views 5

A Second Shot with Electric Dreams Miguel Pantoja, once on the rocky road of life choices, now lights up Northern California with his spark — quite literally. Walking out of federal prison, his mind was set as firmly as a bolt: first stop was a burger, second was a plan to transform his past into a new beginning. That path took him to UEI College in Sacramento, where...

Continue Reading
AMD CEO, Global Leaders Converge At IMPERIA Summit

Updated Category News Views 5

A Clash of Giants in New York The trade floors are buzzing in New York as the world's economic heavyweights and tech titans gather for the inaugural IMPERIA Summit. You can almost smell the pressure and ambition wafting through the streets when folks like AMD's CEO, Lisa Su, share the stage with geopolitical power players like President Trump and China's President Xi...

Continue Reading
Brands Must Choose: Cost or Value Leadership?

Updated Category News Views 6

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Continue Reading
BeyondCPG Accelerator Launches Seventh Growth Program

Updated Category News Views 4

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 8

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
United Apartment Group's Leadership Revamp Signals Growth

Updated Category News Views 7

A Bold Leadership Expansion Big moves are afoot at United Apartment Group (UAG). They're not just refilling some roles here; they're rebooting their lineup with serious hitters—Woody Stone and Lenzie O’Connor are now steering the ship on business development and client services, eager to drive the company to new heights. Woody Stone: Fueled by Experience Stone isn't...

Continue Reading
VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Updated Category News Views 5

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Trading Success: The Math Advantage Guide Unveiled

Updated Category News Views 197

Trading Busters International Launches Educational Guide Trading Busters International, a renowned trading education and community platform, has recently released a new educational guide titled The Math Advantage: Why Smart Traders Ignore Charts and Win with Statistics & Probabilities. This guide is available at no cost to members of the Trading Busters community and...

Continue Reading
Neuberger Berman Fund Announces Exciting Monthly Distribution

Updated Category News Views 196

Monthly Distribution Announcement from Neuberger Berman Neuberger Berman Real Estate Securities Income Fund Inc. (NYSE: NRO) has recently made an announcement regarding its month-to-month distribution plans. This decision is part of its regular distribution strategy, emphasizing its commitment to deliver consistent returns to its investors. Details of the Distribution The...

Continue Reading
Jaywing PLC Shareholder Circular Sees Key Code Updates

Updated Category News Views 94

Jaywing PLC Provides Update on Shareholder Circular Jaywing PLC has announced some significant updates to its shareholder circular, particularly concerning changes to the Takeover Code. This alteration aims to bring clarity to stakeholders in the ever-evolving framework of corporate governance. Details of the Amendment The recent changes were announced following a prior...

Continue Reading
Investors Alert: Claims Investigation for Warner Bros. Discovery

Updated Category News Views 101

Investors Encouraged to Act on Warner Bros. Discovery Claims Faruqi & Faruqi, LLP, a prominent name in securities law, has launched an investigation aimed at protecting investors of Warner Bros. Discovery (NASDAQ: WBD). If you have incurred losses of over $100,000, it is crucial to know your rights. Josh Wilson, a partner at the firm, is reaching out to those impacted to...

Continue Reading
High-Grade Glioma Market Set for Expansive Growth by 2036

Updated Category News Views 5

High-Grade Glioma Market: A Sweeping Overview When it comes to high-grade gliomas, we're talking aggressive brain tumors—no joke. This market's on the upswing, thanks to breakthroughs in diagnostics and treatments. Now, isn't that something? It's like this beast that's finally getting its chains rattled by advancements in targeted therapies, immunotherapies, and...

Continue Reading